70. Bioorg Med Chem. 2018 Jul 17. pii: S0968-0896(18)30433-4. doi:10.1016/j.bmc.2018.07.026. [Epub ahead of print]Incorporation of histone deacetylase inhibitory activity into the core oftamoxifen - A new hybrid design paradigm.Palermo AF(1), Diennet M(2), El Ezzy M(2), Williams BM(1), Cotnoir-White D(2),Mader S(3), Gleason JL(4).Author information: (1)Department of Chemistry, McGill University, 801 Sherbrooke W., Montreal, QCH3A 0B8, Canada.(2)Institute for Research in Immunology and Cancer, Pavillon Marcelle-Coutu,Université de Montréal, 2950 chemin de Polytechnique, Montréal, QC H3T 1J4,Canada.(3)Institute for Research in Immunology and Cancer, Pavillon Marcelle-Coutu,Université de Montréal, 2950 chemin de Polytechnique, Montréal, QC H3T 1J4,Canada; Biochemistry Department, Pavillon Roger-Gaudry, Université de Montréal,2900 Bd Edouard Montpetit, Montréal, QC H3T 1J4, Canada; Centre de Recherche duCHUM, Université de Montréal, Montréal, QC H2X 0A9, Canada.(4)Department of Chemistry, McGill University, 801 Sherbrooke W., Montreal, QCH3A 0B8, Canada. Electronic address: jim.gleason@mcgill.ca.Hybrid antiestrogen/histone deacetylase (HDAC) inhibitors were designed byappending zinc binding groups to the 4-hydroxystilbene core of4-hydroxytamoxifen. The resulting hybrids were fully bifunctional, and displayed high nanomolar to low micromolar IC50 values against both the estrogen receptor α(ERα) and HDACs in vitro and in cell-based assays. The hybrids wereantiproliferative against ER+ MCF-7 breast cancer cells, with hybrid 28bpossessing an improved activity profile compared to either 4-hydroxytamoxifen or SAHA. Hybrid 28b displayed gene expression patterns that reflected both ERα andHDAC inhibition.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.bmc.2018.07.026 PMID: 30078609 